Wutah dodolan YoY sajrone rolas wulan kepungkur: sol-gel.com (SLGL)

Sol-Gel Technologies (SLGL) innovations in acne drug delivery are establishing a new standard of care, although the company's strategy relies on receiving royalties from partners. The company's TTM revenue compound annual growth rate resolves this contradiction, and the -92.70 metric determines this level. However, the business's Israeli origin creates significant geopolitical risks for operational stability.
Ringkesan rincian data analitis Sol-Gel Technologies Ltd. (SLGL)

Sol-Gel Technologies (SLGL) relies on external contractors for the production and testing of its dermatological products. By analyzing the year-over-year sales growth rate over a rolling four-quarter period, an investor can discern the actual efficiency of this outsourcing model. This metric measures the percentage change in revenue over 12 months on a daily basis, smoothing out quarterly gaps. This allows for an assessment of management's ability to scale the business through partners. Stable dynamics confirm operational resilience, whereas sharp declines signal systemic risks.